Pyxis Oncology (NASDAQ:PYXS) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Key Points

• Pyxis Oncology reported a quarterly loss of $0.40 per share, missing analysts’ consensus estimate by $0.06.
• Shares traded around $3.01, with the stock’s market capitalization at approximately $190.7 million; the stock has risen from its 12-month low of $1.03 but remains below its $5.55 high.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and a $7.50 target price, although some firms recently downgraded the shares or reduced their price targets.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.06), Zacks reports.

Pyxis Oncology Stock Performance

Shares of Pyxis Oncology stock traded down $0.17 during mid-day trading on Thursday, hitting $3.01. 1,264,919 shares of the stock were exchanged, compared to its average volume of 1,623,279. The company has a market capitalization of $190.68 million, a P/E ratio of -2.30 and a beta of 1.31. The company has a 50-day simple moving average of $2.53 and a 200 day simple moving average of $1.96. Pyxis Oncology has a 12 month low of $1.03 and a 12 month high of $5.55.

Wall Street Analyst Weigh In

A number of analysts have weighed in on PYXS shares. Wall Street Zen cut shares of Pyxis Oncology from a "hold" rating to a "sell" rating in a research note on Saturday, May 16th. Leerink Partners reduced their price target on Pyxis Oncology from $9.00 to $7.00 and set an "outperform" rating on the stock in a report on Thursday, July 2nd. Wells Fargo & Company assumed coverage on Pyxis Oncology in a research note on Monday, August 3rd. They issued an "overweight" rating and a $12.00 price objective for the company. Wedbush began coverage on shares of Pyxis Oncology in a research report on Tuesday, May 5th. They set an "outperform" rating and a $6.00 target price on the stock. Finally, Weiss Ratings lowered shares of Pyxis Oncology from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, June 30th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Pyxis Oncology presently has a consensus rating of "Moderate Buy" and a consensus target price of $7.50.

Institutional Investors Weigh In On Pyxis Oncology

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Maia Wealth LLC purchased a new position in Pyxis Oncology during the 4th quarter valued at about $25,000. Engineers Gate Manager LP bought a new stake in Pyxis Oncology during the 4th quarter worth approximately $26,000. Fox Run Management L.L.C. purchased a new stake in Pyxis Oncology in the 4th quarter worth approximately $26,000. XTX Topco Ltd bought a new position in Pyxis Oncology in the 2nd quarter valued at $40,000. Finally, LPL Financial LLC grew its position in shares of Pyxis Oncology by 150.7% during the 4th quarter. LPL Financial LLC now owns 35,102 shares of the company's stock valued at $40,000 after purchasing an additional 21,100 shares in the last quarter. 39.07% of the stock is currently owned by institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology NASDAQ: PYXS is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company's platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source